Affiliation:
1. Lysulin, Inc., San Diego, California, USA
Abstract
When a diabetes treatment is changed, patients are eager to see their FBG and A1c changes as a result on the new treatment. We examined these changes in 20 subjects with Type 2 diabetes for 1 week prior to starting Lysulin and then for the following 30 days. While both FBG and A1c drop in less than 1 month, the change in A1c was more rapid than the change if FBG. Possible reasons for the differences between FBG and A1c are presented
Publisher
Edelweiss Publications Inc
Reference8 articles.
1. Rhinesmith T, Turkete T, and Root-Bernstein R. Rapid non-enzymatic glycation of the insulin receptor under hyperglycemic conditions inhibits insulin binding in vitro: implications for insulin resistance (2017) Int J Mol Sci. 18: 2602-2612. https://10.3390/ijms18122602
2. https://www.cdc.gov/diabetes/data/statistics/statistics- report.html
3. Scicchitano P, Cameli M, Maria Maiello M , Modesti PA, uiesan ML, et.al. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics (2014) J Functional Foods 6: 11-32. https://doi.org/10.1016/j.jff.2013.12.006
4. Burd J. Lysulin™, A new supplement for nutritional support for people with diabetes and pre-diabetes (those at risk of developing diabetes) (2018) Diabetes Management 8: 38-40.
5. Burd JF, Noetzel V, Gonzalez A and Melero FAA. Lysulin®: A double-blind placebo controlled pilot study of daily oral supplementation in people with type 2 diabetes (2018) Diabetes Management 8: 154-162.